![]() |
市场调查报告书
商品编码
1588566
全球流式细胞仪市场 - 2024-2031Global Flow Cytometry Market - 2024-2031 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
概述
2023年,全球流式细胞仪市场规模达到47.6亿美元,预计2031年将达到82.4亿美元,2024-2031年预测期间复合年增长率为7.1%。
流式细胞仪是一种识别和量化悬浮在液体介质中的细胞或颗粒的物理和化学特性的先进方法。这项技术能够在单一细胞经过雷射光束时进行快速检查,并根据其光散射和萤光特性进行照明和评估。
流式细胞仪是一种雷射驱动技术,可识别和测量细胞或颗粒的不同特征,例如大小、粒度和使用萤光标记的特定蛋白质标记。这种方法可以让医疗保健专业人员分析血液、骨髓和其他体液样本。它对于透过检测和表征各种细胞类型来诊断癌症和感染等疾病特别有价值。
司机
慢性病发生率上升和技术进步
全球流式细胞仪市场的需求是由多种因素所驱动的。主要因素之一是慢性病发病率上升和技术进步。癌症、糖尿病和心血管疾病等慢性病的盛行率不断上升,大大推动了对流式细胞仪等先进诊断工具的需求。早期诊断对于改善慢性病患者的治疗效果至关重要。流式细胞仪可快速且准确地分析细胞特征,使医疗保健专业人员能够在早期阶段检测到异常情况。
此外,流式细胞仪技术的不断进步,特别是高通量流式细胞仪(HTFC)和光谱流式细胞仪的出现,大大提高了资料分辨率并促进更复杂的分析。 HTFC 能够每秒检查数千个细胞,这对于广泛的研究工作至关重要。例如,HyperCyt 等系统可从多孔板快速加载样品,每分钟处理多达 40 个孔。这种快速通量对于药物发现和筛选过程至关重要,其中快速分析大量样品至关重要。
此外,行业产品发布和批准的主要参与者将推动该市场的成长。例如,2024 年 5 月,安捷伦科技公司推出了 NovoCyte Opteon 光谱流式细胞仪,标誌着流式细胞仪可及性的重大进步。这项创新系统为基础研究、药物发现和治疗开发等各领域的流量资料取得、分析和报告建立了新的基准。
此外,IDEX Health & Science 于 2024 年 1 月推出了 Semrock 系列 Nanopede 滤光片,专为流式细胞仪应用而设计。 Nanopede 滤光片经过精心设计,可提供高传输率,同时有效阻挡整个光谱中不需要的光(光密度 OD5)。这确保了流式细胞仪期间收集的萤光讯号清晰准确。
同样,2023 年 11 月,CD Bioarticles 宣布推出一系列新的流式细胞仪颗粒,其中包括专为流式细胞仪实验校准和标准化而设计的各种类型的聚苯乙烯颗粒。
限制
设备成本高昂和个人缺乏意识等因素预计将阻碍市场的发展。
Overview
The global flow cytometry market reached US$ 4.76 billion in 2023 and is expected to reach US$ 8.24 billion by 2031 growing with a CAGR of 7.1% during the forecast period 2024-2031.
Flow cytometry is an advanced method to identify and quantify the physical and chemical traits of cells or particles suspended in a liquid medium. This technique enables the swift examination of individual cells as they move past a laser beam, where they are illuminated and evaluated based on their light scattering and fluorescence characteristics.
Flow cytometry is a laser-driven technique that identifies and measures different characteristics of cells or particles, such as size, granularity, and specific protein markers using fluorescent labeling. This method allows healthcare professionals to analyze blood, bone marrow, and other bodily fluids samples. It is especially valuable for diagnosing diseases like cancer and infections by detecting and characterizing various cell types.
Market Dynamics: Drivers
Rising incidence of chronic diseases and technological advancements
The demand for the global flow cytometry market is driven by multiple factors. One of the primary factors is the rising incidence of chronic diseases and technological advancements. The increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disorders is significantly driving the demand for advanced diagnostic tools like flow cytometers. Early diagnosis is essential for enhancing patient outcomes in chronic diseases. Flow cytometry provides quick and accurate analysis of cellular characteristics, allowing healthcare professionals to detect abnormalities at earlier stages.
Furthermore, continuous technological advancements in flow cytometry technology, particularly the emergence of high-throughput flow cytometry (HTFC) and spectral flow cytometry, are greatly improving data resolution and facilitating more intricate analyses. HTFC enables the examination of thousands of cells per second, which is vital for extensive research efforts. For instance, systems like HyperCyt allow for swift sample loading from multi-well plates, processing up to 40 wells every minute. This rapid throughput is essential in drug discovery and screening processes, where analyzing large quantities of samples quickly is crucial.
In addition, key players in the industry product launches and approvals that would drive this market growth. For instance, in May 2024, Agilent Technologies Inc. unveiled the NovoCyte Opteon Spectral Flow Cytometer, marking a significant advancement in flow cytometry accessibility. This innovative system establishes a new benchmark for acquiring, analyzing, and reporting flow data across various fields, including basic research, drug discovery, and therapy development.
Also, in January 2024, IDEX Health & Science launched the Semrock line of Nanopede Optical Filters, specifically designed for flow cytometry applications. The Nanopede filters are engineered to provide high transmission rates while effectively blocking unwanted light (optical density OD5) across the spectrum. This ensures that the fluorescence signals collected during flow cytometry are clear and accurate.
Similarly, in November 2023, CD Bioparticles announced the launch of a new range of Flow Cytometry Particles, which includes various types of polystyrene particles specifically designed for calibration and standardization in flow cytometry experiments.
Restraints
Factors such as high equipment costs, and lack of awareness among individuals, are expected to hamper the market.
The global flow cytometry market is segmented based on product type, technology, application, end-user, and region.
The reagents and consumables segment accounted for approximately 43.9% of the global flow cytometry market share
The reagents and consumables segment is expected to hold the largest market share over the forecast period. The reagents and consumables segment is a crucial element of the flow cytometry market, significantly contributing to its growth and application across multiple domains. This segment includes a variety of essential products for performing flow cytometry assays, such as antibodies, assays, kits, and various other reagents.
Moreover, key players in the industry have innovative product launches & approvals and technological advancements that would drive this market growth. For instance, in August 2024, Bio-Rad Laboratories, Inc. announced the launch of annexin V conjugated to eight StarBright Dyes: SBUV400, SBUV795, SBV440, SBV515, SBV790, SBB675, SBB765, and SBY800. These new Annexin V StarBright conjugates facilitate the detection of early apoptotic cells through flow cytometry and provide researchers with a broader selection of fluorophore options. This expansion enhances the ability to incorporate apoptosis detection into multicolor immunophenotyping panels for both conventional and full-spectrum flow cytometry applications.
Also, in May 2023, Sysmex Corporation launched its Clinical Flow Cytometry System, which includes the Flow Cytometer XF-1600 and Sample Preparation System PS-10, along with antibody reagents and related products in Japan. The introduction of the XF-1600 is anticipated to greatly enhance workflow efficiency in clinical laboratories by minimizing manual tasks and promoting standardization. This development aligns with Sysmex's dedication to improving diagnostic capabilities and tackling medical challenges through innovative solutions.
Similarly, in March 2024, Beckman Coulter Life Sciences received 510(k) clearance from the Food and Drug Administration (FDA) to distribute its DxFLEX Clinical Flow Cytometer in the United States. This development brings the widely used benchtop IVD flow cytometry system to American laboratories while enhancing their testing capabilities. The DxFLEX system supports up to 13 colors, and additional detectors can be activated as laboratory needs change, eliminating the necessity for new hardware purchases.
North America accounted for approximately 44.8% of the global flow cytometry market share
North America region is expected to hold the largest market share over the forecast period owing to the growing prevalence of chronic diseases, especially cancer and immunodeficiency disorders, which is a significant factor driving the flow cytometry market. The American Cancer Society indicated that around 1.9 million new cancer cases would be diagnosed in the U.S. in 2022, which would drive the need for effective diagnostic tools like flow cytometry. As healthcare professionals increasingly seek faster and more precise diagnostic methods, the importance of flow cytometry continues to rise.
Technological advancements in flow cytometry are significantly enhancing its capabilities, leading to better resolution and sensitivity in quantifying different cell types. Innovations like multi-parameter analysis enable thorough immunophenotyping, which is vital for diagnosing and tracking diseases such as leukemia and lymphoma. Additionally, the launch of new instruments and software solutions is further driving market growth.
Moreover, in this region, a major number of key player's presence, well-advanced healthcare infrastructure, and government initiatives & regulatory support, and investment in research and development would drive this market growth. For instance, in June 2023, in New Jersey, BD (Becton, Dickinson and Company) announced the global launch of a new automated instrument designed for preparing samples for clinical diagnostics using flow cytometry. This innovative system facilitates a complete "walkaway" workflow solution aimed at enhancing standardization and reproducibility in cellular diagnostics.
Also, in May 2023, in New Jersey BD (Becton, Dickinson and Company) announced the global launch of an innovative cell sorting instrument that incorporates two innovative technologies, significantly enhancing the capabilities of flow cytometry.
The major global players in the flow cytometry market include Becton, Dickinson and Company, Danaher Corporation (Beckman Coulter), Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Miltenyi Biotec, Sysmex Corporation, bioMerieux, Cytek Biosciences, and Apogee Flow Systems Ltd. among others.
The global flow cytometry market report would provide approximately 70 tables, 65 figures, and 184 pages.
LIST NOT EXHAUSTIVE